MCID: MLG074
MIFTS: 50

Malignant Mesenchymoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Malignant Mesenchymoma

MalaCards integrated aliases for Malignant Mesenchymoma:

Name: Malignant Mesenchymoma 12 53 15
Malignant Mesenchymal Tumor 53 44 73
Rat Malignant Renal Mesenchymal Tumor 73
Mesenchymoma, Malignant 12
Sarcoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5758
MeSH 44 C535700
NCIt 50 C4268
SNOMED-CT 68 89623007

Summaries for Malignant Mesenchymoma

MalaCards based summary : Malignant Mesenchymoma, also known as malignant mesenchymal tumor, is related to gallbladder sarcoma and mesenchymoma. An important gene associated with Malignant Mesenchymoma is MB (Myoglobin), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Doxil and Fusilev have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Malignant Mesenchymoma

Diseases in the Mesenchymoma family:

Benign Mesenchymoma Malignant Mesenchymoma
Adult Malignant Mesenchymoma

Diseases related to Malignant Mesenchymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 gallbladder sarcoma 31.9 DES KIT MYOD1 MYOG
2 mesenchymoma 31.8 DES MB MDM2 MYOD1
3 liposarcoma 30.2 CDK4 DES EWSR1 MB MDM2 TP53
4 soft tissue sarcoma 30.1 EWSR1 MDM2 TP53
5 malignant fibroxanthoma 30.1 CDK4 DES MDM2 MYOD1
6 cystic nephroma 30.1 DES KIT WT1
7 suppressor of tumorigenicity 3 30.0 CDKN1A FHIT TP53
8 histiocytoma 29.7 EWSR1 KIT MB MDM2 MYOD1 TP53
9 sarcoma 29.6 CDK4 EWSR1 KIT MDM2 SSX2B TP53
10 sarcoma, synovial 29.5 DES KIT MDM2 SSX2B
11 rhabdomyosarcoma 29.5 CDK4 DES EWSR1 MB MDM2 MYOD1
12 leiomyosarcoma 29.4 CDK4 DES KIT MB MDM2 MYOG
13 childhood malignant mesenchymoma 12.2
14 adult malignant mesenchymoma 12.2
15 prostate embryonal rhabdomyosarcoma 10.3 KIT MYOD1
16 giant cell myocarditis 10.3 DES MB
17 ovarian fibrothecoma 10.3 DES KIT
18 malignant triton tumor 10.3 DES MB MYOD1
19 botryoid rhabdomyosarcoma 10.3 DES MB MYOD1
20 spindle cell rhabdomyosarcoma 10.3 DES MB MYOD1
21 adult mesoblastic nephroma 10.2 ETV6 NTRK3
22 alveolar soft part sarcoma 10.2 DES MB MYOD1
23 myofibroma 10.2 DES ETV6 MB
24 spindle cell sarcoma 10.2 DES MDM2 NTRK3
25 spindle cell lipoma 10.2 CDK4 DES MDM2
26 zika virus infection 10.2 MDM2 TP53
27 mixed liposarcoma 10.2 CDK4 MB MDM2
28 ischemic fasciitis 10.2 CDK4 DES MDM2
29 congenital fibrosarcoma 10.2 DES ETV6 NTRK3
30 infiltrating angiolipoma 10.2 CDK4 MDM2
31 lipomatosis, multiple 10.2 CDK4 DES MDM2
32 cutaneous ganglioneuroma 10.2 KIT NCAM1
33 fibrosarcoma of bone 10.2 CDK4 KIT MDM2
34 sclerosing liposarcoma 10.2 MB MDM2 TP53
35 leiomyoma 10.2
36 testicular gonadoblastoma 10.2 KIT WT1
37 orbital cancer 10.2 MB NCAM1
38 myxosarcoma 10.2 MB MDM2 TP53
39 breast secretory carcinoma 10.2 CDK4 ETV6 NTRK3
40 mixed cell type cancer 10.2 KIT MB TP53
41 cellular myxoid liposarcoma 10.2 CDK4 EWSR1 MDM2
42 orbit rhabdomyosarcoma 10.2 MB MYOG
43 deep leiomyoma 10.2 CALD1 KIT
44 ring chromosome 7 10.1 CDK4 MDM2 TP53
45 carcinosarcoma 10.1 DES KIT TP53
46 myositis 10.1 MB MYOD1 NCAM1
47 fallopian tube carcinosarcoma 10.1 NCAM1 WT1
48 pediatric fibrosarcoma 10.1 ETV6 EWSR1 NTRK3
49 kidney sarcoma 10.1 MB WT1
50 ewing's family of tumors 10.1 CDK4 EWSR1 KIT

Graphical network of the top 20 diseases related to Malignant Mesenchymoma:



Diseases related to Malignant Mesenchymoma

Symptoms & Phenotypes for Malignant Mesenchymoma

GenomeRNAi Phenotypes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.51 WT1 SSX2B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.51 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.51 EWSR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.51 WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.51 EWSR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.51 NTRK3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.51 EWSR1 NTRK3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.51 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.51 EWSR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.51 SSX2B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.51 EWSR1 KIT NTRK3 WT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.51 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.51 EWSR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.51 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.51 EWSR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.51 WT1 SSX2B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.51 WT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.51 KIT NTRK3 WT1 SSX2B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.51 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.51 NTRK3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.51 EWSR1 KIT NTRK3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.51 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.51 WT1 SSX2B
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.51 EWSR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.51 SSX2B
26 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.51 EWSR1 SSX2B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.51 KIT NTRK3 WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.51 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.51 EWSR1 KIT
30 Reduced mammosphere formation GR00396-S 9.17 CDK4 DES ETV6 GALNT3 MDM2 NCAM1

MGI Mouse Phenotypes related to Malignant Mesenchymoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 CDK4 CDKN1A DES ETV6 GALNT3 KIT
2 growth/size/body region MP:0005378 10.37 CDK4 CDKN1A ETV6 GALNT3 KIT MB
3 homeostasis/metabolism MP:0005376 10.37 CDK4 CDKN1A DES ETV6 FHIT GALNT3
4 mortality/aging MP:0010768 10.31 CDK4 CDKN1A DES ETV6 FHIT KIT
5 cellular MP:0005384 10.3 CDK4 CDKN1A DES ETV6 GALNT3 KIT
6 digestive/alimentary MP:0005381 10.25 CDK4 CDKN1A ETV6 FHIT GALNT3 KIT
7 hematopoietic system MP:0005397 10.25 CDK4 CDKN1A ETV6 FHIT GALNT3 KIT
8 embryo MP:0005380 10.19 CDK4 CDKN1A ETV6 KIT MB MDM2
9 integument MP:0010771 10.18 CDK4 CDKN1A ETV6 FHIT GALNT3 KIT
10 muscle MP:0005369 10.14 CDK4 CDKN1A DES GALNT3 KIT MB
11 liver/biliary system MP:0005370 10.06 CDK4 CDKN1A KIT MDM2 PNLIP TP53
12 neoplasm MP:0002006 10.02 CDK4 CDKN1A ETV6 FHIT KIT MDM2
13 no phenotypic analysis MP:0003012 9.97 CDKN1A ETV6 KIT MDM2 MYOD1 MYOG
14 normal MP:0002873 9.91 CDK4 ETV6 KIT MDM2 MYOD1 MYOG
15 renal/urinary system MP:0005367 9.76 CDK4 CDKN1A GALNT3 KIT MDM2 TP53
16 reproductive system MP:0005389 9.61 CDK4 CDKN1A GALNT3 KIT MDM2 MYOD1
17 respiratory system MP:0005388 9.28 CDKN1A KIT MB MYOD1 MYOG NTRK3

Drugs & Therapeutics for Malignant Mesenchymoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
3
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997
5
Votrient 18 49 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Malignant Mesenchymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
2
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
3
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
4
Mechlorethamine Approved, Investigational Phase 3,Phase 1 51-75-2 4033
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Mesna Approved, Investigational Phase 3 3375-50-6 598
7
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
8
Irinotecan Approved, Investigational Phase 3,Phase 2 100286-90-6, 97682-44-5 60838
9
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
10
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
11
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
12
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
13
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
14
Morphine Approved, Investigational Phase 3 57-27-2 5288826
15
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
16
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18
Camptothecin Experimental Phase 3,Phase 2 7689-03-4
19
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
20 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
21 Immunosuppressive Agents Phase 3,Phase 2
22 topoisomerase I inhibitors Phase 3,Phase 2
23 Etoposide phosphate Phase 3,Phase 2
24 Alkylating Agents Phase 3,Phase 2,Phase 1
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
27 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
30 Antirheumatic Agents Phase 3,Phase 2
31 Anti-Infective Agents Phase 3,Phase 2
32 Adjuvants, Immunologic Phase 3,Phase 1
33 Antimitotic Agents Phase 3,Phase 2
34 Immunologic Factors Phase 3,Phase 2,Phase 1
35
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
36
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
37
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
38
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
39
Gemcitabine Approved Phase 2 95058-81-4 60750
40 Protein Kinase Inhibitors Phase 2,Phase 1
41 Imatinib Mesylate Phase 2,Phase 1 220127-57-1 123596
42 Angiogenesis Modulating Agents Phase 2,Phase 1
43 Angiogenesis Inhibitors Phase 2,Phase 1
44 Antimetabolites Phase 2
45 Antiviral Agents Phase 2
46 Antimetabolites, Antineoplastic Phase 2
47 Protective Agents Phase 2
48 razoxane Phase 2
49 Cardiotonic Agents Phase 2
50 Antibodies, Monoclonal Phase 1

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Unknown status NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
2 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
3 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
4 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
5 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
6 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
12 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
13 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
14 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
15 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
16 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
17 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
18 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
19 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
20 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
22 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
23 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
24 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
25 Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma Active, not recruiting NCT00077285 Phase 2 carboplatin;cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
26 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
27 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
28 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
29 NHS-IL12 for Solid Tumors Recruiting NCT01417546 Phase 1 NHS-IL-12
30 Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX Unknown status NCT00900211
31 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
32 Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma Withdrawn NCT00334984 Not Applicable glutamine

Search NIH Clinical Center for Malignant Mesenchymoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: malignant mesenchymal tumor

Genetic Tests for Malignant Mesenchymoma

Anatomical Context for Malignant Mesenchymoma

MalaCards organs/tissues related to Malignant Mesenchymoma:

41
Bone, Lung, Heart, Kidney, Liver, Prostate, Myeloid

Publications for Malignant Mesenchymoma

Articles related to Malignant Mesenchymoma:

(show top 50) (show all 143)
# Title Authors Year
1
Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study. ( 29211298 )
2018
2
Primary malignant mesenchymoma of bladder: Case report and review of the literature. ( 28796040 )
2017
3
Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: Lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. ( 27459057 )
2017
4
Critical reappraisal of primary osseous composite sarcoma (malignant mesenchymoma) - analysis of four cases and literature review. ( 27102568 )
2016
5
Pulsed radiofrequency treatment of piriformis syndrome in a pregnant patient with malignant mesenchymal tumor. ( 28111733 )
2016
6
Malignant mesenchymal tumor of male breast: primary chondrosarcoma. ( 25821574 )
2015
7
Malignant mesenchymal tumor of the sacrum. ( 26022672 )
2015
8
Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog. ( 25132008 )
2014
9
The treatment of paravertebral malignant mesenchymal tumor pain with cryoablation. ( 25037025 )
2014
10
Diagnosis and treatment considerations in a case of malignant mesenchymoma in an African fur seal (Arctocephalus pusillus). ( 23805568 )
2013
11
Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee. ( 22154650 )
2012
12
Metastatic leiomyosarcoma of the uterus with heterologous differentiation to malignant mesenchymoma. ( 22833086 )
2012
13
Malignant mesenchymoma of the heart base in a dog with infiltration of the pericardium and metastasis to the lung. ( 22516086 )
2012
14
Combined cutaneous sarcoma: pleomorphic liposarcoma and conventional osteosarcoma-the so-called malignant mesenchymoma. ( 23082265 )
2012
15
Malignant mesenchymoma in the nasal cavity of a bull. ( 21306728 )
2011
16
Malignant mesenchymal tumor with leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, and osteosarcoma differentiation: case report and literature review. ( 21496258 )
2011
17
An intra-abdominal malignant mesenchymoma associated with nonabsorbable sutures in a ferret (Mustela putorius furo). ( 20224105 )
2010
18
Malignant mesenchymoma surrounding the esophageal hiatus. ( 20103193 )
2010
19
Malignant mesenchymoma of the thyroid: case report and literature review. ( 20572598 )
2010
20
A primary hepatic malignant mesenchymal tumor with myofibrogenic differentiation in a B6C3F1 mouse. ( 19332665 )
2009
21
Malignant Mesenchymal Tumor of the Breast: Primary Chondrosarcoma. ( 20847886 )
2009
22
Brachial plexus neuroma mimicking local recurrence of malignant mesenchymal tumor after forequarter amputation. ( 19292195 )
2008
23
Surgical case of giant malignant mesenchymoma in the posterior mediastinum that recurred in the bilateral mediastinum. ( 18781043 )
2008
24
Uterine malignant mesenchymoma, arising in a leiomyoma, with pulmonary metastases. ( 17257144 )
2007
25
Left atrial malignant mesenchymoma--emergency resection and mitral replacement. ( 17664193 )
2007
26
Intermandibular malignant mesenchymoma in a crossbreed dog. ( 16961475 )
2006
27
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. ( 15994146 )
2005
28
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. ( 15728225 )
2005
29
Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature. ( 15601312 )
2004
30
Malignant mesenchymal tumor arising from cherubism: a case report. ( 15170291 )
2004
31
Malignant mesenchymoma arising from a uterine leiomyoma in the menopause. ( 15581987 )
2004
32
Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. ( 15792374 )
2004
33
Malignant mesenchymoma of the orbit: case report and review of the literature. ( 12578773 )
2003
34
Severe and prolonged hypoglycemia triggered by long-acting octreotide in a patient with malignant mesenchymal tumor: case report. ( 12678421 )
2003
35
Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis. ( 12792727 )
2003
36
Post-transfusion acute graft versus host disease in a 17-year-old girl with a malignant mesenchymal tumor--report of a case. ( 15055161 )
2003
37
Malignant mesenchymoma of the pleura. ( 17670075 )
2003
38
Retroperitoneal malignant mesenchymoma: a case of mesenchymal mixed tumor with osteosarcoma, leiomyosarcoma, liposarcoma and fibrosarcoma. ( 12514345 )
2002
39
Malignant mesenchymoma of the uterus, arising in a leiomyoma. ( 11903599 )
2002
40
Radical resection of a malignant mesenchymoma with hypogastric artery transposition. ( 12210036 )
2002
41
Primary malignant mesenchymoma of the heart. ( 11788281 )
2002
42
Malignant mesenchymoma of the lower leg. ( 11684725 )
2001
43
Giant malignant mesenchymoma of the spermatic cord with bidirectional differentiation. ( 11441285 )
2001
44
Retroperitoneal malignant mesenchymoma: imaging findings in five cases. ( 9933683 )
1999
45
Ring chromosomes in a malignant mesenchymoma. ( 10087943 )
1999
46
Malignant mesenchymoma associated with an unusual vasoinvasive metastasis in a dog. ( 9657162 )
1998
47
Primary left atrial malignant mesenchymoma: a case report. ( 9607271 )
1998
48
Malignant mesenchymoma arising in an incisional scar of the abdominal wall. ( 9800981 )
1998
49
MALIGNANT MESENCHYMOMA - AN UNUSUAL PRESENTATION IN A CHILD: A Case Report. ( 28775495 )
1998
50
Radiation-induced malignant mesenchymoma of the chest wall following treatment for breast cancer. ( 9166083 )
1997

Variations for Malignant Mesenchymoma

Expression for Malignant Mesenchymoma

Search GEO for disease gene expression data for Malignant Mesenchymoma.

Pathways for Malignant Mesenchymoma

Pathways related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.8 CDK4 CDKN1A KIT MDM2 TP53
2 12.77 CDK4 CDKN1A KIT MDM2 TP53
3
Show member pathways
12.68 CDK4 CDKN1A FHIT MDM2 TP53
4
Show member pathways
12.61 CDK4 CDKN1A MDM2 TP53 UCHL1
5
Show member pathways
12.3 CDK4 CDKN1A MDM2 TP53
6 12.28 CDK4 CDKN1A MDM2 TP53
7 12.19 CDK4 CDKN1A MDM2 TP53
8 12.18 CDK4 CDKN1A MDM2 TP53
9
Show member pathways
12.12 CDK4 CDKN1A MDM2 TP53
10 12.04 CDK4 CDKN1A MDM2 TP53
11
Show member pathways
12.04 CDK4 CDKN1A MDM2 NTRK3 TP53
12 11.82 CDK4 CDKN1A MDM2 TP53
13 11.81 CDK4 CDKN1A MDM2 NTRK3 TP53
14
Show member pathways
11.77 CDKN1A MDM2 TP53
15 11.73 CDKN1A MDM2 TP53
16 11.71 CDKN1A KIT MYOD1
17 11.7 CDK4 CDKN1A MYOD1
18 11.7 CDK4 CDKN1A FHIT TP53
19 11.66 CDKN1A MDM2 TP53
20 11.61 CDK4 CDKN1A MDM2 TP53
21 11.58 KIT NTRK3 TP53
22 11.49 CDKN1A MDM2 MYOD1
23 11.49 CDK4 CDKN1A MDM2 TP53
24 11.44 CDKN1A TP53 UCHL1
25 11.44 CDKN1A ETV6 EWSR1 MDM2 SSX2B TP53
26 11.29 CDKN1A MYOD1 TP53
27 11.19 CDK4 CDKN1A TP53
28 11.18 CDK4 MDM2 TP53
29 11.12 CDK4 CDKN1A MDM2 TP53
30
Show member pathways
10.92 CDKN1A MDM2 TP53
31 10.9 CDK4 CDKN1A MDM2 TP53
32 10.73 CDKN1A TP53
33
Show member pathways
10.5 CDKN1A TP53

GO Terms for Malignant Mesenchymoma

Cellular components related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.5 CDK4 CDKN1A ETV6 EWSR1 MDM2 TP53
2 nuclear body GO:0016604 9.46 CDKN1A MDM2 MYOD1 TP53
3 cytosol GO:0005829 9.44 CALD1 CDK4 CDKN1A DES ETV6 FHIT

Biological processes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.77 KIT MDM2 NTRK3 TP53 WT1
2 heart development GO:0007507 9.73 MB MDM2 NTRK3 WT1
3 response to toxic substance GO:0009636 9.7 CDK4 CDKN1A MDM2
4 response to hyperoxia GO:0055093 9.51 CDK4 CDKN1A
5 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.5 CDKN1A MDM2 TP53
6 myotube differentiation GO:0014902 9.49 MYOD1 MYOG
7 positive regulation of phospholipase C activity GO:0010863 9.48 KIT NTRK3
8 replicative senescence GO:0090399 9.46 CDKN1A TP53
9 negative regulation of apoptotic process GO:0043066 9.43 CDKN1A KIT MDM2 NTRK3 TP53 WT1
10 positive regulation of skeletal muscle fiber development GO:0048743 9.4 MYOD1 MYOG
11 muscle cell fate commitment GO:0042693 9.26 MYOD1 MYOG
12 signal transduction by p53 class mediator GO:0072331 9.16 CDKN1A TP53
13 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53
14 cell differentiation GO:0030154 10.01 ETV6 KIT MYOD1 MYOG NTRK3 TP53

Molecular functions related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 p53 binding GO:0002039 9.33 MDM2 NTRK3 TP53
2 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.26 MYOD1 MYOG TP53 WT1
3 ubiquitin protein ligase binding GO:0031625 9.1 CDKN1A FHIT MDM2 MYOD1 TP53 UCHL1

Sources for Malignant Mesenchymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....